Zu den Inhalten springen

Tumorzentrum Freiburg - CCCF

Prof. Dr. Manfred Jung

Contact:

Institute of Pharmaceutical Sciences
Albert-Ludwigs-Universität Freiburg
Albertstraße 25
79104 Freiburg i.Br.
Phone. +49 761 203-4896
Fax +49 761 203-6351
manfred.jung@pharmazie.uni-freiburg.de
Arbeitskreis Prof. Jung

Current Positions:

  • Vice Dean of the Department of Chemistry and Pharmacy
  • Director of the Institute for Pharmaceutical Sciences
  • Co-speaker of the Collaborative Research Centre 992 Medical Epigenetics and Coordinator of its Integrated Research Training Group

Research Focus

The group focuses on assay development and the synthesis of inhibitors of histone modifying enzymes especially on zinc dependent histone deacetylases (HDACs), NAD+ dependent histone deacetylases (sirtuins), histone acetyltransferases (HATs) and histone demethylases.)

  • CRC 992: Principal Investigator of project A04 Chemical epigenetics: Inhibitors of JMJC-domain containing histone demethylases
  • SPP 1463 Lead of Project: Reversible histone acetylation and its inhibitors in myeloid neoplasia
  • DFG Research Training Group RTG1976  ‘Functional diversity of cofactors in Enzymes’ Project: NAD-dependent histone deacetylase smSirt2 from Schistosoma mansoni.www.cofactor-diversity.uni-freiburg.de.
  • FRIAS-Projekt ‘Structure based epigenetic drug discovery’: Collaboration project of Prof. Jung, Prof, Oliver Einsle (structural biochemistry) and Prof. Wolfgang Sippl (chemmical informatics) aimed to establish the basis for structure based epigenetic drug research in Freiburg.http://www.frias.uni-freiburg.de/de/das-institut/archiv-frias/irg/fellows/jung/#FRIAS-Projekt
  • DFG project: Strukturbasierte Entwicklung und biologische Charakterisierung von selektiven Inhibitoren der Histon-Desacetylasen (HDACs) 8 und 10

DKTK Research Topics:

  • LACID: LSD1 as anticancer target in the clinic (TRANSATRA) and in drug discovery
  • Inhibitors of histone code reader proteins

DKTK Research Platform Drug Development:

LSD1 inhibitors as new anticancer agents

Research Group Members DKTK:

Johannes Schulz-Fincke
Dr. Alexander-Thomas Hauser (Core Support)
Alexandra Walter    

Website of the Research Group Prof. Jung:
http://www.pharmazie.uni-freiburg.de/chemie/german/professoren/akjunghp/

 

DKTK Publications:

Reinhardt H, Trittler R, Eggleton AG, Wöhrl S, Epting T, Buck M, Kaiser S, Jonas D, Duyster J, Jung M, Hug MJ, Engelhardt M. Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach. J Natl Compr Canc Netw. April 2017;15(4):484–93.

Wagner T, Greschik H, Burgahn T, Schmidtkunz K, Schott A-K, McMillan J, Baranauskienė L, Xiong Y, Fedorov O, Jin J, Oppermann U, Matulis D, Schüle R, Jung M. Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform. Nucleic Acids Research. 17. Februar 2016;gkw089.

Slynko I, Schmidtkunz K, Rumpf T, Klaeger S, Heinzlmeir S, Najar A, Metzger E, Kuster B, Schüle R, Jung M, Sippl W. Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing. ChemMedChem [Internet]. Juli 2016 [zitiert 5. August 2016]; Verfügbar unter: doi.wiley.com/10.1002/cmdc.201600284

Schiffmann I, Greve G, Jung M, Lübbert M. Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics. 15. November 2016;00–00.

Robaa D, Wagner T, Luise C, Carlino L, McMillan J, Flaig R, Schüle R, Jung M, Sippl W. Identification and Structure-Activity Relationship Studies of Small-Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1. ChemMedChem [Internet]. September 2016 [zitiert 7. Oktober 2016]; Verfügbar unter: doi.wiley.com/10.1002/cmdc.201600362

Ostrovskyi D, Rumpf T, Eib J, Lumbroso A, Slynko I, Klaeger S, Heinzlmeir S, Forster M, Gehringer M, Pfaffenrot E, Bauer SM, Schmidtkunz K, Wenzler S, Metzger E, Kuster B, Laufer S, Schüle R, Sippl W, Breit B, Jung M. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1). Future Medicinal Chemistry [Internet]. 30. August 2016 [zitiert 5. September 2016]; Verfügbar unter: www.future-science.com/doi/10.4155/fmc-2016-0132

Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clinical Epigenetics [Internet]. Dezember 2016 [zitiert 31. Mai 2016];8(1). Verfügbar unter: clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-016-0223-4

Haas J, Schätzle MA, Husain SM, Schulz-Fincke J, Jung M, Hummel W, Müller M, Lüdeke S. A quinone mediator drives oxidations catalysed by alcohol dehydrogenase-containing cell lysates. Chem Commun. 2016;52(29):5198–201.

Chakrabarti A, Melesina J, Kolbinger FR, Oehme I, Senger J, Witt O, Sippl W, Jung M. Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases. Future Medicinal Chemistry [Internet]. 30. August 2016 [zitiert 5. September 2016]; Verfügbar unter: www.future-science.com/doi/10.4155/fmc-2016-0117

Rapino F, Abhari BA, Jung M, Fulda S. NIK is required for NF-κB-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways. Cell Death and Disease. 12. März 2015;6(3):e1692.

Gajer JM, Furdas SD, Gründer A, Gothwal M, Heinicke U, Keller K, Colland F, Fulda S, Pahl HL, Fichtner I, Sippl W, Jung M. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis. 9. Februar 2015;4(2):e137.

Franz H, Greschik H, Willmann D, Ozretić L, Jilg CA, Wardelmann E, Jung M, Buettner R, Schüle R. The histone code reader SPIN1 controls RET signaling in liposarcoma. Oncotarget. 6. März 2015;

Dahl, E., Jung, A., Fassunke, J., Hummel, M., Penzel, R., Dietmeier, W., Lassmann, S. Chances and Risks of blood-based molecular pathological Analysis of circulating Tumor Cells (CTC) and cell free DNA (cfDNA) in personalized Cancer Therapy A Statement of the Working Group „Liquid Biopsy“ of the AG Molecular Pathology ini the German Society for Pathology (DGP). Der Pathologe. 2015;36:92–7.

Other:

Schmitt ML, Ladwein KI, Carlino L, Schulz-Fincke J, Willmann D, Metzger E, u. a. Heterogeneous Antibody-Based Activity Assay for Lysine Specific Demethylase 1 (LSD1) on a Histone Peptide Substrate. Journal of Biomolecular Screening [Internet]. 31. März 2014 [zitiert 11. Juni 2014]; Verfügbar unter: jbx.sagepub.com/cgi/doi/10.1177/1087057114529156

Fermento ME, Gandini NA, Salomón DG, Ferronato MJ, Vitale CA, Arévalo J, López Romero A, Nuñez M, Jung M, Facchinetti MM, Curino AC. Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization. Exp Mol Pathol. 2014 Sep 18;97(3):411-424. doi: 10.1016/j.yexmp.2014.09.019. [Epub ahead of print] PubMed PMID: 25240203.

Carneiro VC, de Abreu da Silva IC, Torres EJ, Caby S, Lancelot J, Vanderstraete M, Furdas SD, Jung M, Pierce RJ, Fantappié MR. Epigenetic changes modulate schistosome egg formation and are a novel target for reducing transmission of schistosomiasis. PLoS Pathog. 2014 May 8;10(5):e1004116. doi: 10.1371/journal.ppat.1004116. eCollection 2014 May. PubMed PMID: 24809504; PubMed Central PMCID: PMC4014452.

Wagner T, Robaa D, Sippl W, Jung M. Mind the methyl: methyllysine binding proteins in epigenetic regulation. ChemMedChem. 2014 Mar;9(3):466-83. doi: 10.1002/cmdc.201300422. Epub 2014 Jan 21. PubMed PMID: 24449612.

Lucas X, Wohlwend D, Hügle M, Schmidtkunz K, Gerhardt S, Schüle R, Jung M, Einsle O, Günther S. 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. doi: 10.1002/anie.201307652. Epub 2013 Nov 24. PubMed PMID: 24272870

-- Logo: © dkfz.de

Prof. Dr. Christoph Peters
Tumorzentrum Freiburg CCCF
Phone: +49-761-270-71500
Hugstetter Str. 49
79106 Freiburg

and

Institute of Molecular Medicine and Cell Research
University of Freiburg
Stefan-Meier-Str. 17
79104 Freiburg
Phone: +49-761-203-9600/9601
christoph.peters@mol-med.uni-freiburg.de​​

Dr. Anja Hernández
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
++49 (0)761 270 22810
anja.hernandez@dkfz-heidelberg.de

Dr. Anna Dost
Deutsches Krebsforschungszentrum (DKFZ)
Im Neuheimer Feld 280
69120 Heidelberg
+49 (0)761 270 77121
a.dost@dkfz-heidelberg.de